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Introduction
Dengue is the most important arboviral
infection of humans. In endemic countries
the scale of the dengue disease burden
imparts an economic cost [1] and strains
fragile health care systems. There are no
licensed vaccines for prevention of dengue,
and the public health response in endemic
countries relies mostly on combating the
principal mosquito vector, Aedes aegypti, via
insecticides and breeding site removal. The
sustained transmission of dengue in endem-
ic settings together with its increasing global
footprint indicates existing disease control
strategies have been unsuccessful [2].
Novel vector control approaches to limit
dengue virus (DENV) transmission include
release of Ae. aegypti that carry transgenes
that result in highly penetrant, dominant,
late-acting, female-specific lethality [3]. In
field cage experiments, the release of such
mosquitoes in sufficient numbers results in
eradication of the mosquito population
[4]. Another strategy involves embryonic
introduction of the obligate intracellular
insect bacterium, Wolbachia, into strains of
Ae. aegypti [5]. Strikingly, Wolbachia-infect-
ed Ae. aegypti are partially resistant to
infection with DENV [6], and by virtue
of the intrinsic capacity of some strains of
Wolbachia to invade insect populations
[6,7], there is the prospect of achieving
widespread biological resistance to DENV
amongst Ae. aegypti populations. The life-
shortening impact of some Wolbachia
strains could also contribute to reductions
in disease transmission [5]. The first
entomological field trials of mosquitoes
infected with Wolbachia (wMel and wMel-
Pop strains) have now been successfully
carried out in Cairns, Australia and have
demonstrated that Wolbachia can establish
itself at very high prevalence in field
populations of Ae. aegypti [7]. However,
the prospects of demonstrating reduction
in DENV transmission in Cairns are slim
given the episodic, imported nature of
dengue outbreaks in this region.
A critical challenge for all entomological
approaches to control of vector-borne
disease is how best to demonstrate efficacy
in reducing disease transmission [8]. In
principal, the high force of infection in
dengue endemic countries should assist an
evidence-gathering approach to this chal-
lenge. However, a feature of dengue
epidemiology is that it is spatially and
temporally heterogeneous [9–11]. Thus
oscillations in disease incidence over time
are common for a given region of
transmission, and within each region it is
common for focal ‘‘hot spots’’ of transmis-
sion to exist [3]. This heterogeneity in
transmission means that uncontrolled ob-
servational studies of dengue transmission
in a community where, for example,
Wolbachia-infected Ae. aegypti have been
released could take many years or decades
to yield evidence that is suggestive of a
benefit. Equally, the heterogeneity of den-
gue transmission poses challenges to tradi-
tional clinical trial approaches, as does the
non-stationary nature of mosquito popula-
tions [8]. Here we review design and
statistical considerations relevant to the
conduct of clinical trials of these novel
interventions and the practical challenges
posed by the epidemiology of dengue in
endemic settings. Whilst our discussion of
trial design is focused on Wolbachia-infected
Ae. aegypti, it is also relevant to other vector
control interventions, such as genetically
engineered male mosquitoes carrying a
dominant lethal gene [4], insecticide-im-
pregnated nets [12], or larvacides [13].
Methods
Cluster randomised trials (CRTs) are
the gold standard design to provide
evidence on the efficacy of an intervention
that has community-wide impact [14].
Cluster formation is a crucial aspect of
the design of a CRT and requires prior
mapping of the study area with respect to
dengue sero-prevalence, demographics,
and information on movement of individ-
uals. Experience from the Cairns (Austra-
lia) release shows that it is feasible to
achieve a prevalence of Wolbachia infec-
tion in A. aegypti mosquitoes of nearly
100% in treatment clusters within 6
months after first release [7]. Clusters
need to be sufficiently geographically
separated to ensure that A. aegypti mosqui-
toes present in control clusters remain
virtually free of Wolbachia for the entire
study period.
We consider the incidence of DENV-
seroconversions during a trial as a suitable
primary endpoint and DENV-naı¨ve chil-
dren aged 2–5 years living in each cluster
as an optimal ‘‘sentinel’’ cohort for
serological surveillance. Young children
are less likely to spend substantial periods
of time outside of their residence and local
community (and hence outside of the
‘‘treatment umbrella’’) than more mobile
older children and adults. In addition,
DENV-prevalence in older children is
higher and those remaining naı¨ve and
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hence eligible for the study are potentially
less representative of the full population
(for example, for socio-economic reasons).
Two alternative designs are considered.
The first is the classical parallel two-armed
cluster randomised trial (PCRT) in which
each recruited cluster is randomised to
intervention or control, and the interven-
tion is implemented simultaneously across
the relevant clusters. Thus the control
clusters provide contemporaneous controls
for the intervention clusters. The other
design considered is a stepped wedge
cluster randomised trial (SWCRT) in
which each cluster is assigned to the
control treatment initially and clusters
are subsequently crossed-over to the
intervention in a random selection at fixed
time points until eventually all clusters are
under treatment [15,16]. As dengue is a
seasonal disease, selected cross-over time
points should reflect this. As an example,
for a 3-year study period, the SWCRT
has: all clusters as controls for year 1; half
of the clusters as controls and half as
intervention, randomly selected, for year
2; and all clusters on intervention in year
3. Diagrams of both designs are provided
in Text S1.
SWCRTs have been most frequently
used for evaluating interventions during
routine implementation such as the evalua-
tion of a vaccine on the community level
following a successful individual randomised
trial. From a logistic perspective, they are
attractive, because the intervention can be
rolled out in a step-wise fashion and
evaluated. As clusters are their own controls,
SWCRTs are less sensitive to between-
cluster variation and thus might require a
lower sample size compared to parallel
designs [15]. However, strong temporal
effects may greatly reduce the precision of
estimates as all clusters start out in the
control arm and end as intervention clusters.
Secular trends of dengue during the study
period could confound the treatment effect
causing bias. SWCRTs are less flexible for
trial adaptations such as an extension of the
follow-up period if the observed DENV-
incidence is lower than expected, as all
clusters have already crossed-over to the
intervention at this time point.
Cluster size and cluster separation are
important considerations in the design of
all CRTs, but they require particular
attention in trials of vector control inter-
ventions, for which entomological and
community considerations need be taken
into account. Entomological consider-
ations include the dispersal of Wolbachia-
infected mosquitoes to ensure a persistent
and homogenous effect in treatment
clusters without undue contamination into
untreated clusters that serve as controls.
For dengue trials community consider-
ations include the extent of daily move-
ment within and between clusters that the
surveillance cohorts are likely to under-
take; if the clusters are too small this
movement may be excessive, and cause
further reduction in any treatment effect.
Thus, data on movement patterns of
children eligible to join the surveillance
cohort together with more information on
the limits of spatial dispersal of Wolbachia-
infected mosquitoes are essential before
the cluster formation stage of any trial. An
approach that is widely adopted in CRTs
is the so-called ‘‘fried-egg’’ design [14], in
which the whole cluster receives the
allocated treatment but only the inner
area of the cluster (the ‘‘egg-yolk’’) is used
for surveillance since the treatment effect
in this inner area is less affected by spill-
over from neighbouring clusters that may
be in the opposite treatment arm. We
would therefore suggest that the surveil-
lance cohort in each cluster be drawn from
this inner area of each cluster.
Sample Size Requirements of a
CRT
Sample size requirements for CRTs of a
Wolbachia intervention (or other communi-
ty-based intervention) depend critically on
the size of the intervention effect and on
both the magnitude and the variability
(temporal and spatial) of seroconversion
rates between clusters. To assess this
variability in an example, we used pub-
lished data from 12 primary schools in
Kamphaeng Phet, Thailand, followed over
a 3-year period [10] where the overall
Figure 1. Sample size estimates for a PCRT or a SWCRT. Total number of clusters required for a PCRT (black lines) or a SWCRT (blue lines)
depending on the size of the intervention effect. Solid lines correspond to 90% power, dashed lines to 80% power. Simulations are based on
parameters determined from the Kamphaeng Phet dengue cohort (Thailand) (described in [10]) with three time periods each of 1-year duration, a
surveillance cohort of 100 children in each cluster, and a two-sided significance level of 5%.
doi:10.1371/journal.pntd.0001937.g001
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yearly DENV infection incidences were
7.9%, 6.5%, and 2.2%.
A mixed-effects Poisson-regression mod-
el fitted to these data gave coefficients of
variation (cv, i.e., SD/mean) for yearly
DENV infection incidence of 0.27 for
between-school variation, 0.57 for annual
variation, and 0.85 for residual variation
(i.e., variation that cannot be explained by
systematic spatial or temporal variation,
respectively, and corresponds to localized
school and year specific variation). A
detailed description of the model used to
derive these coefficients of variation can be
found in Text S1. The overall between-
school coefficient of variation over the 3-
year period was 0.52. The same model fit to
data from 43 villages in Cambodia [9], also
showed that temporal and residual varia-
tion are more pronounced than spatial
variation (unpublished data).
We then used the incidence and vari-
ability data reported above to simulate
hypothetical PCRT and SWCRT trials.
Additional assumptions for the trial simu-
lations were a study duration of 3 years
and a surveillance cohort of 100 children
in each cluster. We varied the intervention
effect between a 40% and an 80%
decrease of DENV seroconversion in
intervention clusters compared to controls.
Allowing for the fact that some children in
intervention clusters will experience infec-
tions outside of the intervention area, we
regard an effect of a 50%–60% reduction
as realistic in our target population.
Details regarding the set-up of the simu-
lation study and the statistical analysis of
simulated trials are provided in Text S1.
Results
Sample size requirements for the two
designs and for varying treatment effects
are shown in Figure 1 and requirements for
several alternative scenarios are given in
Text S1. The required total sample sizes to
detect a 60% or 50% reduction of dengue
in the intervention arm with 80% power
were 20 or 32 clusters, respectively, for a
PCRT compared to 40 or 72 clusters for a
SWCRT. The SWCRT design generally
required substantially higher sample sizes
except in the unrealistic situation of spatial
but no temporal or residual variation.
Conclusions
A parallel cluster-randomised trial is the
design of choice for testing novel entomo-
logical methods of dengue control. Under
realistic assumptions we show it to require
a substantially lower sample size than a
stepped wedge design. Sample size re-
quirements for a parallel design are
relatively modest; our example gave a
minimum sample size of 20 clusters (ten
per study arm) with each cluster providing
100 person-years of follow-up per year and
a follow-up duration of 3 years. Although
careful planning and substantial funding
are required to run such a trial, the
benefits of having a robust evidence-base
from which to promote programmatic
roll-out and/or further optimisation of
the strategy should prove invaluable.
Supporting Information
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to compare PCRT versus SWCRT designs.
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